Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer

Authors: Jiao Hu, Anze Yu, Belaydi Othmane, Dongxu Qiu, Huihuang Li, Chao Li, Peihua Liu, Wenbiao Ren, Minfeng Chen, Guanghui Gong, Xi Guo, Huihui Zhang, Jinbo Chen, Xiongbing Zu - Theranostics 2021 cited by 454

Anti-Siglec15 immunotherapy might be suitable for BLCA treatment as Siglec15 correlates with a non-inflamed TME in BLCA. Siglec15 could also predict the molecular subtype and the response to several treatment options.